ReviewParasitology2013
Genetic dissection of drug resistance in trypanosomes.
Review in Parasitology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Pathogenic Significance of Trypanosomatids: Progress in Drug Resistance, Control Strategies, and Artificial Intelligence.Interdisciplinary perspectives on infectious diseases · 2026Review
- A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis.Antimicrobial agents and chemotherapy · 2025Article
- Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose.Journal of medicinal chemistry · 2023Article
- Overexpression ofInternational journal of molecular sciences · 2022Article
- The power and promise of genetic mapping from Plasmodium falciparum crosses utilizing human liver-chimeric mice.Communications biology · 2021Article
- Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda.International journal for parasitology. Drugs and drug resistance · 2021Article
- Article
- Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.Genes · 2020Review
- An Overview of Drug Resistance in Protozoal Diseases.International journal of molecular sciences · 2019Review
- Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei.Antimicrobial agents and chemotherapy · 2019Article
- Optimising genetic transformation of Trypanosoma cruzi using hydroxyurea-induced cell-cycle synchronisation.Molecular and biochemical parasitology · 2018Article
- Histone deacetylases as targets for antitrypanosomal drugs.Future science OA · 2018Review
- Human Kinetoplastid Protozoan Infections: Where Are We Going Next?Frontiers in immunology · 2018Review
- Decoding the network of Trypanosoma brucei proteins that determines sensitivity to apolipoprotein-L1.PLoS pathogens · 2018Article
- Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.Scientific reports · 2017Article
- Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs.Molecular microbiology · 2017Article
- Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.PLoS neglected tropical diseases · 2017Article
- Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.International journal for parasitology. Drugs and drug resistance · 2016Article
- Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes.The Journal of antimicrobial chemotherapy · 2016Article
- Leishmania is not prone to develop resistance to tamoxifen.International journal for parasitology. Drugs and drug resistance · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The trypanosomes cause two neglected tropical diseases, Chagas disease in the Americas and African trypanosomiasis in sub-Saharan Africa. Over recent years a raft of molecular tools have been developed enabling the genetic dissection of many aspects of trypanosome biology, including the mechanisms underlying resistance to some of the current clinical and veterinary drugs. This has led to the identification and characterization of key resistance determinants, including transporters for the anti-Trypanosoma brucei drugs, melarsoprol, pentamidine and eflornithine, and the activator of nifurtimox-benznidazole, the anti-Trypanosoma cruzi drugs. More recently, advances in sequencing technology, combined with the development of RNA interference libraries in the clinically relevant bloodstream form of T. brucei have led to an exponential increase in the number of proteins known to interact either directly or indirectly with the anti-trypanosomal drugs. In this review, we discuss these findings and the technological developments that are set to further revolutionise our understanding of drug-trypanosome interactions. The new knowledge gained should inform the development of novel interventions against the devastating diseases caused by these parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.